71 results
8-K
EX-99.2
INSM
Insmed Incorporated
28 May 24
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
6:30am
, for a Commercial Webinar Insmed’s commercial leadership will provide details on the market outlook for ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and TPIP
8-K
EX-99.1
INSM
Insmed Incorporated
28 May 24
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
6:30am
forward to hosting a commercial webinar on Tuesday, June 4, 2024, at 8:00 am ET, where the Company’s commercial leadership will provide details
8-K
EX-99.2
ggv6y48k t13q1
8 May 23
Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, “The
7:45am
8-K
EX-99.1
8vzfux0emve aji
23 May 22
Insmed Names Drayton Wise Chief Commercial Officer
8:05am
8-K
EX-99.1
2z4rhowryd5xd
1 Oct 20
Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day
12:00am
8-K
EX-99.1
b11ydc0jnibu
25 Feb 20
Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
7:31am
8-K
EX-99.1
m76bti
30 Jan 20
Insmed Appoints Sara Bonstein as Chief Financial Officer
7:59am